YANG Ci-qiu, WANG Kun, CHEN Yuan-qi. The First Prospective Randomized Controlled Phase ⅢClinical Study of Pembrolizumab Combined With Chemotherapy as Neoadjuvant Treatment for Early Triple-Negative Breast Cancer[J]. Journal of Evidence-Based Medicine, 2021, 21(2): 83-86. DOI: 10.12019/j.issn.1671-5144.2021.02.005
|
Citation:
|
YANG Ci-qiu, WANG Kun, CHEN Yuan-qi. The First Prospective Randomized Controlled Phase ⅢClinical Study of Pembrolizumab Combined With Chemotherapy as Neoadjuvant Treatment for Early Triple-Negative Breast Cancer[J]. Journal of Evidence-Based Medicine, 2021, 21(2): 83-86. DOI: 10.12019/j.issn.1671-5144.2021.02.005
|
YANG Ci-qiu, WANG Kun, CHEN Yuan-qi. The First Prospective Randomized Controlled Phase ⅢClinical Study of Pembrolizumab Combined With Chemotherapy as Neoadjuvant Treatment for Early Triple-Negative Breast Cancer[J]. Journal of Evidence-Based Medicine, 2021, 21(2): 83-86. DOI: 10.12019/j.issn.1671-5144.2021.02.005
|
Citation:
|
YANG Ci-qiu, WANG Kun, CHEN Yuan-qi. The First Prospective Randomized Controlled Phase ⅢClinical Study of Pembrolizumab Combined With Chemotherapy as Neoadjuvant Treatment for Early Triple-Negative Breast Cancer[J]. Journal of Evidence-Based Medicine, 2021, 21(2): 83-86. DOI: 10.12019/j.issn.1671-5144.2021.02.005
|
DownLoad: